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Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenera-
tive disorder that affects the striatum most severely. However, except
for juvenile forms, relative preservation of the cerebellum has been
reported. The objective of the present study was to perform MRI
measurements of caudate, putamen, cerebral, and cerebellar volumes
and correlate these findings with the length of the CAG repeat and
clinical parameters. We evaluated 50 consecutive patients with HD
using MRI volumetric measurements and compared them to normal
controls. Age at onset of the disease ranged from 4 to 73 years (mean:
43.1 years). The length of the CAG repeat ranged from 40 to 69 (mean:
47.2 CAG). HD patients presented marked atrophy of the caudate and
putamen, as well as reduced cerebellar and cerebral volumes. There
was a significant correlation between age at onset of HD and length of
the CAG repeat, as well as clinical disability and age at onset. The
degree of basal ganglia atrophy correlated with the length of the CAG
repeat. There was no correlation between cerebellar or cerebral vol-
ume and length of the CAG repeat. However, there was a tendency to
a positive correlation between duration of disease and cerebellar
atrophy. While there was a negative correlation of length of the CAG
repeat with age at disease onset and with striatal degeneration, its
influence on extrastriatal atrophy, including the cerebellum, was not
clear. Extrastriatal atrophy occurs later in HD and may be related to
disease duration.
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Introduction
Huntington’s disease (HD) is a domi-
nantly inherited neurodegenerative disorder
that usually manifests in adulthood, result-
ing in familial adult onset chorea and sub-
cortical dementia (1). In HD, the protein
huntingtin is enlarged because of an ex-
tended CAG repeat chain present on the
short arm of chromosome 4 (1,2). To date,
the exact function of huntingtin is unknown
and there is no information about its three-
dimensional structure that suggests any pu-
tative function. The defect of this protein
promotes neuronal apoptosis in various brain
regions, especially the basal ganglia, and the
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caudate nucleus in particular. Most descrip-
tions were limited exclusively to damage to
the striatum (3). However, neuronal degen-
eration also occurs in other areas of the brain
(4-6). Generally the cerebellum is spared in
the adult form, and in the great majority of
patients the cerebellar changes have been
reported to be discrete (5,6).
The length of the CAG repeat in the mutant
gene has important implications for age at
onset, penetrance, and stability of the gene
between generations (7). While the relation-
ship between CAG repeat and age at onset is
relevant, the effect of trinucleotide length on
the rate of HD progression is less clear. Al-
though some investigators have suggested that
larger CAG expansions result in more rapid
progression (7), two prospective studies have
failed to demonstrate a clear relationship be-
tween CAG repeat and illness progression (8-
10). A plausible hypothesis to explain this
discrepancy point is the instability in the length
of the CAG repeat (10).
In the present study, we measured cau-
date, putamen, cerebral, and cerebellar vol-
umes in a large series of HD patients and
controls and we determined whether the HD
genotype is associated with regional differ-
ences in brain structure, age at onset, dura-
tion of disease, and clinical disability.
Subjects and Methods
Subjects
All 50 consecutive patients studied had
a clinical and molecular diagnosis of HD
performed at the Neurogenetics clinic of
UNICAMP. For each patient, age at onset of
HD was determined by asking the patient
and multiple unaffected family members to
recollect the first occurrence of chorea, ri-
gidity, irritability, sleep disturbance, frequent
falls, sexual dysfunction, loss of energy,
altered social behavior, or failing memory
that was not an isolated incident but her-
alded a progressive decline. The control sub-
jects, 14 men and 19 women ranging in age
from 18 to 55 years (mean age: 34 years;
standard deviation, SD: 12.15), were healthy
and had no family history of neurological or
psychiatric illness. We excluded patients with
significant co-morbidities, such as alcohol-
ism, head injury, arterial hypertension, dia-
betes mellitus, stroke, drug abuse, and ma-
lignancy. Neurological exams were per-
formed in all patients by the same investiga-
tor (HHR). All subjects gave written in-
formed consent to participate in this study,
which was approved by the Ethics Commit-
tee of our University Hospital. All patients
had known trinucleotide repeats.
Clinical and molecular investigation
We used a structured clinical question-
naire for patients and family members. Each
subject underwent formal motor examina-
tion. Subjects were scored according to the
motor component of the United Huntington’s
Disease Rating Scale (UHDRS) (11). Clini-
cal and genetic details of each patient were
included in a database. Molecular testing
was performed according to international
standard protocols for laboratory testing of
HD. Genomic DNA was isolated from pe-
ripheral lymphocyte by standard methods.
PCR amplification of the CAG repeat in the
IT15 gene was performed with primers HD1
and HD3 (1,12), which are adjacent to the
CAG stretch. PCR reactions were performed
in a total volume of 12.5 µL containing 100
ng of genomic DNA, 1.6 MM of each dNTP
(dATP, dGTP, dTTP), 4 pmol of each primer,
5% DMSO, 0.2 U perfect match (Stratagene®,
La Jolla, CA, USA), and 0.5 units Taq DNA
polymerase. After an initial denaturation of
2 min at 95ºC the amplification was accom-
plished in 30 cycles at the following tem-
peratures: denaturing at 94ºC for 1 min,
annealing at 50ºC for 1 min, and extension at
72ºC for 2 min, followed by a final extension
at 72ºC for 7 min. PCR products were sepa-
rated by electrophoreses through a 6% dena-
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turing polyacrylamide gel. Gels were trans-
ferred into Hybond N+ nylon membranes
and hybridized with an α-32 P 3'-end labeled
(CAG) 15 probe. Allele lengths were deter-
mined by comparing migration relative to a
sequencing ladder. Alleles were considered
normal when they contained less than 35
CAGs and expanded when they contained
more than 40 CAGs (13). We then assigned
the patients to three subgroups: patients with
early onset HD (N = 4, 2 males and 2 fe-
males, mean age at onset 8 years), patients
with classical onset HD (N = 24, 8 males and
16 females, mean age at onset 30 years), and
patients with late onset HD (N = 22, 19 males
and 3 females, mean age at onset 44 years).
Magnetic resonance imaging acquisition
Magnetic resonance imaging was obtained
with a 2 Tesla system (Elscint Prestige®, Haifa,
Israel). Images were acquired on the coronal,
sagittal, and axial planes. Our HD protocol
consists of: a) sagittal T1 spin-echo, 6 mm
thick (repetition time (TR), 430; echo time
(TE), 12) for optimal orientation of the subse-
quent images; b) coronal T1 inversion recov-
ery, 3 mm thick (flip angle = 200º; TR = 2700
ms; TE = 14 ms; T1 = 840 ms; matrix = 130 x
256; field of view (FOV) = 16 x 18 cm); c)
coronal T2-weighted fast spin-echo, 3 mm
thick (flip angle = 120º; TR = 4800 ms; TE =
129 ms; matrix = 252 x 320; FOV = 18 x 18
cm); d) axial images parallel to the long axis of
the hippocampus; T1 gradient echo, 3 mm
thick (flip angle = 70º; TR = 200 ms; TE = 5
ms; matrix = 180 x 232; FOV = 22 x 22 cm);
e) axial T2 fast spin-echo, 4 mm thick (flip
angle = 120º; TR = 6800 ms; TE = 129 ms;
matrix = 252 x 328; FOV = 21 x 23 cm).
Volumetric studies
Basal ganglia and cerebral volumes were
measured using coronal inversion recovery
images and cerebellar volume was measured
using sagittal T1 spin-echo acquisition. Cau-
date and putamen structures and total intra-
cranial and cerebellar volumes (Figure 1)
were manually delineated using the NIH
Image program (http://rsb.info.nih.gov/nih-
image). The volume of each region was com-
pared to that of the control group of 33
healthy volunteers. Values below two SD
from the mean for the control group were
considered abnormal.
Figure 1. Samples of coronal
and sagittal magnetic resonance
imaging from a patient with
Huntington’s disease (top row)
and a normal control (bottom
row) showing the outlines of cau-
date and putamen (left), cere-
bral (center) and cerebellar vol-
umes (right).
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Statistical analysis
We report the minimum, maximum and
mean values and SD for the volumes of the
structures analyzed, and P values less than
0.05 were accepted as statistically signifi-
cant. We used analysis of variance (ANOVA)
to compare continuous variables between
groups. Left/right asymmetry (asymmetric
index, AI) was calculated according to the
following formula: AI = (left - right)/0.5
(left + right). To assess the relationship be-
tween volumes and length of the CAG re-
peat, and age at onset of the disease we used
Spearman correlation analysis. We used the
Mann-Whitney test to compare AI between
right and left basal ganglia structures and
cerebellar and cerebral volumes. We used
linear regression to assess the relationship
between age at onset of disease and length of
the CAG repeat. For the clinical score analy-
ses we used the Spearman correlation test.
We also performed statistical analyses
comparing the three subgroups of HD sub-
jects according to age at disease onset. We
used ANOVA to compare continuous vari-
ables between groups such as putamen and
caudate nuclei, and clinical analysis. We
used the exact Mann-Whitney test to com-
pare cerebellar and cerebral volumes be-
tween HD and control groups and the
Kruskal-Wallis test when these structures were
compared with the three subgroups of HD.
Results
We studied 50 consecutive patients with
a clinical and molecular diagnosis of HD (21
women and 29 men; mean age: 43.1 years;
SD: 13.25; range: 4 to 73 years) and com-
pared them to normal controls (14 men and
19 women) ranging in age from 18 to 55
years (mean: 34 years; SD: 12.15). The age
at onset of HD ranged from 2 to 66 years
(mean: 35.1 years; SD: 12.19). Among pa-
tients followed at our HD clinic we identi-
Figure 2. Box plot with putamen
(A), caudate (B), cerebellar (C),
and cerebral (D) volumes in 50
patients with Huntington’s dis-
ease (HD) and 33 controls (C).
The box extends from the 25th
percentile to the 75th percentile,
with a horizontal line at the me-
dian (50th percentile). Whiskers
extend down to the smallest
value and up to the largest. RHD
= right-sided volumes in patients
with HD; LHD = left-sided vol-
umes in patients with HD; RC =
right-sided volumes in controls;
LC = left-sided volumes in con-
trols. There was a significant dif-
ference between patients and
controls for all comparisons (P <
0.0001; ANOVA for basal gan-
glia and Mann-Whitney test for
cerebellar and cerebral vol-
umes).
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fied 4 patients with the juvenile form of the
disease (2 women) with a mean age of 14.5
years (SD: 7.85; range: 4 to 21 years) that
were analyzed separately. The CAG repeat
in the HD gene ranged from 40 to 69 (mean:
47.2 CAG; SD: 5.87) and normal alleles
ranged from 18 to 26 CAG units (mean: 22
CAG; SD: 2.65). There was no significant
difference in the length of the expanded
alleles between affected men (mean 45.7;
SD: 3.30) and affected women (mean 49.1;
SD: 7.86; P = 0.08). There was a significant
inverse correlation between age at onset of
the disease and length of the CAG repeat (P
= 0.0001, r = -0.60, Spearman test), but not
between duration of disease and length of
the CAG repeat (P = 0.54, r = -0.08). There
was a marked reduction of caudate and puta-
men nuclei and of cerebral and cerebellar
volume in HD patients, with a significant
difference from controls (P < 0.0001; Figure
2). Left-sided putamen volumes were slightly
smaller than right-sided putamen volumes
(P = 0.05), but there was no asymmetry for
the caudate. There was a significant correla-
tion between the length of the CAG repeat
and the volumes of right caudate (P = 0.024,
r = -0.31), left caudate (P = 0.0047, r =
-0.39), right putamen (P = 0.023, r = -0.32),
and left putamen nuclei (P = 0.05, r = -0.27).
However, there was no correlation between
putamen and caudate volumes and duration
of disease (P = 0.53, r = 0.09 for right
putamen; P = 0.60, r = 0.07 for left putamen;
P = 0.43, r = -0.11 for right caudate; P = 0.49,
r = -0.10 for left caudate). In addition, we did
not find a correlation between the length of
the CAG repeat and cerebellar (P = 0.72, r =
-0.05) or cerebral (P = 0.91, r = -0.01) vol-
umes. We found a tendency to a correlation
between duration of disease and cerebellar
volumes (P = 0.08, r = -0.25), but not cere-
bral volumes (P = 0.48, r = -0.10).
When the juvenile group was compared
to the group of classic and late onset HD,
there was no statistical difference in basal
ganglia, cerebellar or cerebral volume (P =
0.1, P = 0.4, and P = 0.3, respectively). In
addition, we found a highly significant dif-
ference in the mean size of the expanded
allele between early- and late-onset HD and
between classic-onset and late-onset HD (P
< 0.05).
The UHDRS scores ranged from 15 to
128 (mean: 65.5; SD: 33.74; Table 1). There
was a correlation between UHDRS scores
and age at onset (P = 0.03, r = 0.3), and a
tendency for length of the CAG repeat (P =
0.08, r = 0.24), but there was no correlation
between duration of disease, cerebral vol-
ume, right putamen and caudate volumes,
and clinical scores (P > 0.1). Interestingly,
there was a correlation between UHDRS
scores and left putamen volume and a ten-
dency to a correlation between UHDRS score
and left caudate volume (P = 0.05, r = 0.27
and P = 0.07, r = 0.25, respectively).
Discussion
Since the original discovery that the HD
phenotype results from an expanded CAG
trinucleotide repeat within the IT15 gene
located on chromosome 4 (1,2), several hy-
potheses have been raised in an attempt to
explain the mechanisms of expanded CAG
repeats in the pathogenesis of HD. Certain
Table 1. Summary of clinical and molecular data in patients with Huntington’s disease
and controls.
Huntington’s disease Normal controls
(N = 50) (N = 33)
Male:female 29:21 14:19
Age (years; range) 4-73 18-55
Age (years; mean ± SD)   43.1 ± 13.25    34 ± 12.15
Age at onset (years; range) 2-66
Age at onset (years; mean ± SD)   35.1 ± 12.19
CAG repeat (range) 40-69 18-26
CAG repeat (mean ± SD) 47.2 ± 5.87 22 ± 2.65
UHDRS (range) 15-128
UHDRS (mean ± SD):   65.5 ± 33.74
CAG repeat (men; mean ± SD) 45.7 ± 3.30
CAG repeat (women; mean ± SD) 49.1 ± 7.86
UHDRS = United Huntington’s Disease Rating Scale.
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brain areas and also specific neuronal sub-
types differ significantly in their susceptibil-
ity to injury in the course of acute and chronic
disorders, suggesting that specific protec-
tive factors are expressed differently among
neurons or even among different cell types
in the same tissue. This can be clearly seen in
the striatum, where GABAergic projection
cells (12,14-16), but not cholinergic inter-
neurons, are precociously damaged in the
course of HD (12,15-18).
There is evidence of distributed gray
matter pathology and progressive white mat-
ter pathology before the clinical onset of HD
(5,19), and loss of basal ganglia volume has
also been reported in asymptomatic indi-
viduals with HD mutation (20-24), indicat-
ing that striatal neuronal loss occurs before
or early during the clinical course.
Even though striatal atrophy has been
detected and reported by many investigators
(3,25-29), neuronal degeneration also oc-
curs in other areas of the brain such as the
cerebral and cerebellar cortex (4,5), amyg-
dala, hippocampus, and brainstem (6), sup-
porting the concept that HD is a multisystem
disorder. In agreement with this concept,
subcortical gray matter loss in the thalamus,
substantia nigra, and anterior basomedial
diencephalic region has been described, but
in later stages of the disease (5).
It is well known that the most affected
brain structure in HD patients is the striatum
(3). However, the mechanisms underlying
the regional preferences for striatum atrophy
are still controversial. One possible explana-
tion is the instability in the length of the
CAG stretch (10). The resulting poly-
glutamine load can vary as a result of the
regional instability of the CAG mutation
related to the tissue biochemical features
(30), therefore causing different rates of cell
death in different tissues. On the other hand,
there is some evidence that polyglutamine
differs between tissues due to differential
instability of the CAG mutation (30). Per-
haps then the striatum is more vulnerable to
the effects of accumulating mutant huntingtin
than other tissues. Curiously, in our study
left-sided putamen volumes were slightly
smaller than right-sided putamen volumes,
but we did not find asymmetry in caudate
nuclei. Although HD has been generally
considered to be a symmetric disease (31),
findings of higher lactate levels in the left
than in the right striatum have been attrib-
uted to increased motor activation in the
dominant hemisphere, especially increased
glutamatergic synaptic input to striatal cells
(32). In agreement with this finding, based
on the UHDRS motor component, we de-
tected a slight correlation between clinical
disability and left-sided putamen atrophy
and a tendency to a correlation between
clinical disability and left-sided caudate at-
rophy. On the other hand, studies have shown
that the putamen is more affected than the
caudate (27,28), whereas others have shown
the opposite (20,29). Longitudinal data from
neuropathology and neuroimaging studies
suggest that the earliest changes in HD occur
in the caudate nucleus, while the putamen
nucleus is more affected with disease pro-
gression (3,33,34). In agreement with previ-
ous studies (29,31,35,36), we found that the
caudate and putamen were disproportion-
ately atrophic in HD patients, with this atro-
phy correlating with the length of the CAG
repeat, but not with duration of the disease
(23,37). On the other hand, atrophy also
occurred in cerebral and cerebellar volumes,
but without correlation with the length of the
CAG repeat (29,36). In addition, there was a
non-significant trend towards an inverse cor-
relation between cerebellar atrophy and du-
ration of the disease. This may support the
hypothesis that neocortical and cerebellar
degenerations are explained, at least in part,
by retrograde changes due to massive neu-
ronal loss in the striatum or due to progres-
sive white matter loss in the course of the
disease, suggesting that cerebellar neuronal
loss occurs later in the clinical course.
The present results suggest a more wide-
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spread and global disease process in patients
with HD, and that the extent of the degenera-
tion process is not completely explained by
the length of the CAG repeat. Recent evi-
dence showed that environmental factors
modify the onset and progression of neuro-
degeneration (38) and variations in the glu-
tamate receptor 6 genotype may explain up
to 13% of the variability in the age at onset of
HD not accounted for by the length of the
CAG repeat (39,40).
Longitudinal studies with larger series
will be necessary to characterize the exact
rate of atrophy of different brain structures
and to determine the kinetics of neuronal
degeneration during the various stages of
HD and this knowledge could be helpful for
the targeting of new therapeutic measures.
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